Compare Cytokinetics Inc (CYTK) vs Goodyear Tire & Rubber Co (GT) Price & Performance

Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.

Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.

The Goodyear Tire & Rubber Company (GT) trades at $4.69, near its 52-week low, with a bearish technical signal and mixed earnings history. Despite beating EPS estimates in two recent quarters, the company reported a net loss of $1.72 billion in 2025, with negative profit margins and ROE. Cash flow improved slightly in 2025, but high debt levels and declining revenue pose challenges. Recent news highlights restructuring efforts and a 'shrink-to-grow' strategy targeting premium tire segments.

GT presents a high-risk opportunity with a deep value proposition—low P/E and P/B ratios suggest undervaluation, but persistent losses and bearish analyst sentiment indicate significant headwinds. The stock's upside hinges on successful execution of its turnaround plan and margin improvement, while downside risks include ongoing volume pressure and macroeconomic pressures on the auto industry.